The key catalyst to watch is the initial monotherapy data from ASCEND in Q1 2027, particularly the ORR in the first-line NSCLC cohort. Positive data could support Phase 3 initiation and drive re-rating; negative or ambiguous data would delay the program. Also monitor initial data from the chemotherapy combination cohorts in mid-2027 and the APOLLO trial initiation for CR-002.
Price Chart
Executive Summary
Crescent Biopharma provided a clinical pipeline update, highlighting completion of dose escalation in the global Phase 1/2 ASCEND trial of CR-001 (PD-1 x VEGF bispecific) and plans to report initial monotherapy data in Q1 2027. The company also disclosed multiple ongoing and planned combination studies with chemotherapy and ADCs, including a collaboration with Kelun-Biotech, and expects to initiate Phase 3 studies of CR-001 in early 2028. The update is largely operational and lacks new clinical data or financial figures, making it a routine pipeline progress report.
Key Facts
- Dose escalation complete in global Phase 1/2 ASCEND trial of CR-001; more than 125 patients dosed across the US, Europe, and South Korea.
- Initial monotherapy data from ASCEND expected in Q1 2027, including antitumor response from a first-line NSCLC cohort of up to 12 patients.
- Enrollment commenced in standard of care chemotherapy combination expansion cohorts; initial data expected in mid-2027 (Q2/Q3).
- Crescent plans to initiate the first of multiple Phase 3 studies of CR-001 in early 2028, pending results and regulatory interactions.
- Multiple Phase 2 trials of CR-001 in combination with sac-TMT (Kelun-Biotech's TROP2-directed ADC) are ongoing in NSCLC and other solid tumors, with initial data expected in mid-2027.
- CR-002 (PD-L1-targeted ADC) received IND clearance from the FDA; global Phase 1/2 APOLLO trial expected to commence this quarter with initial data in H2 2027.
- Phase 1/2 trial of CR-003 (ITGB6-targeted ADC) ongoing in China; proof-of-concept data expected in Q1 2027.
- Company expects more than 2,000 patients dosed across portfolio by mid-2027.
Financial Impact
No financial data provided in the press release; all metrics are clinical and operational.
Risk Factors
- Clinical data from ASCEND monotherapy and combination cohorts may fail to meet efficacy or safety expectations, delaying Phase 3 plans.
- Reliance on Kelun-Biotech for development and commercialization in Greater China introduces execution and partnership risks.
- Crescent has no approved products or revenue; future capital needs may lead to dilution.
- Competition in PD-1/VEGF bispecific and ADC space is intense, with multiple established and emerging players.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3382144 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $11.84 | awaiting T+60 | — | $12.76 (+7.77%) |
Oct 15, 2026 11d ago | Press Release | $11.84 | awaiting T+60 | — | $12.76 (+7.77%) |
Oct 5, 2026 21d ago | Press Release | $13.94 | awaiting T+60 | — | $12.76 (−8.46%) |
Sep 18, 2026 5w ago | Insider Cluster | $16.25 | awaiting T+60 | — | $12.76 (−21.48%) |
Jul 30, 2026 12w ago | 8-K | $15.02 $12.82 | ▼ −14.65% | ▼ −17.11% | $12.76 (−15.05%) |
Jul 20, 2026 14w ago | Insider Buy | $16.64 $12.91 | ▼ −22.42% | ▼ −26.39% | $12.76 (−23.32%) |
Jul 15, 2026 14w ago | 8-K / 424B5 | $15.11 $14.91 | ▲ +1.32% | ▲ +5.03% | $12.76 (+15.55%) |
Jul 14, 2026 14w ago | Press Release | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $12.76 (+18.57%) |
Jul 14, 2026 14w ago | 424B5 | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $12.76 (+18.57%) |
Jul 13, 2026 15w ago | EFFECT | $15.69 $13.57 | ▼ −13.51% | ▼ −17.51% | $12.76 (−18.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers